Abbisko (HKG:2256) unit Abbisko Therapeutics obtained clearance for the investigational new drug application of ABSK043 from China's National Medical Products Administration, a same-day Hong Kong bourse filing said.
Shares of the biopharmaceutical firm were up 3% in Thursday afternoon trading.
The clearance is for the drug in combination with Shanghai Allist Pharmaceuticals' glecirasib for the treatment of patients with non-small cell lung cancer.
The two companies had entered into a cooperation agreement In March to explore the said combination of drugs.